



## Ocular Surface Disease and Glaucoma Treatments

Guest Editor:

### Dr. Michele Figus

Department of Surgical, Medical,  
Molecular Pathology and Critical  
Care Medicine, University of Pisa,  
56124 Pisa, Italy

Deadline for manuscript  
submissions:

**closed (30 November 2021)**

### Message from the Guest Editor

Glaucoma treatments include medical, surgical and laser therapies. Usually, medications represent first-line therapy. Today, more attention is paid to the ocular surface and how quality of life could be affected by medications. Therefore, the literature about the study of ocular surface disease and glaucoma using new diagnostic tools has increased. Anterior segment-optical coherence tomography and in vivo confocal microscopy have been largely used to detect the early signs of ocular surface alterations and the relationship between the ocular surface and failure of filtering surgery. This is still an unsolved issue. Recently, preservative-free eye drops, both unidose and multidose formulations, and new slow-release devices have been introduced to improve ocular surface health. Besides, laser trabeculoplasty or minimally invasive glaucoma surgery are anticipated to become more widespread in surgical treatment to replace standard anterior filtering surgery.

The purpose of this Special Issue is to illustrate the new developments that are taking place in terms of ocular surface disease diagnosis and improvements in glaucoma patients.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)